Blood microvessel density, lymphatic microvessel density and lymphatic invasion in predicting melanoma metastases: Systematic review and meta-analysis

British Journal of Dermatology

Volumn 170, Issue 1, 2014, Pages 66-77

  Pastushenko, I ^a   Vermeulen, P B ^b   Carapeto, F J ^c   Van Den Eynden, G ^b   Rutten, A ^b   Ara, M ^a   Dirix, L Y ^b   Van Laere, S ^b,d  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b SINT AUGUSTINUS HOSPITAL   (Belgium)

^c UNIVERSITY OF ZARAGOZA   (Spain)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; CANCER PATIENT; CAPILLARY DENSITY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL; LYMPHANGIOGENESIS; MEDLINE; MELANOMA; META ANALYSIS; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PUBLICATION; REVIEW; SYSTEMATIC REVIEW; TUMOR INVASION; LYMPH NODE METASTASIS; MICROVASCULATURE; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; PROGNOSIS; SKIN TUMOR; VASCULARIZATION;

HUMANS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MELANOMA; MICROVESSELS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SKIN NEOPLASMS;

EID: 84892381189     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12688     Document Type: Review

References (69)

1. Bhatia S, Thompson JA,. Systemic therapy for metastatic melanoma in 2012: dawn of a new era. J Natl Comp Canc Netw 2012; 10: 403-12.
2. Falchook GS, Lewis KD, Infante JR, et al,. Activity of oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13: 782-9.
3. Robert C, Thoms L, Bondarenko I, et al,. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-26.
4. Topalian SL, Hodi FS, Brahmer JR, et al,. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54.
5. Emmett MS, Symonds KE, Rigby H, et al,. Prediction of melanoma metastasis by Shields index based on lymphatic vessel density. BMC Cancer 2010; 10: 208.
6. Criscione VD, Weinstock MA,. Melanoma thickness trends in the United States, 1988-2006. J Invest Dermatol 2010; 130: 793-7.
7. Uzzan B, Nicolas P, Cucherat M, Perret GY,. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 2004; 64: 2941-55.
8. Trivella M, Pezzella F, Pastorino U, et al,. Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data. Lancet Oncol 2007; 8: 488-99.
9. Meert AP, Peasmans M, Martin B, et al,. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2002; 87: 694-701.
10. Des GG, Uzzan B, Nicolas P, et al,. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 2006; 94: 1823-32.
11. Straume O, Salvesen HB, Akslen LA,. Angiogenesis is prognostically important in vertical growth phase melanomas. Int J Oncol 1999; 15: 595-9.
12. Valencak J, Heere-Ress E, Kopp T, et al,. Selective immunohistochemical staining shows significant prognostic influence of lymphatic and blood vessels in patients with malignant melanoma. Eur J Cancer 2004; 40: 358-64.
13. Dadras SS, Lange-Asschenfeldt B, Velasco P, et al,. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph node. Mod Pathol 2005; 18: 1232-42.
14. Depasquale I, Thompson WD,. Microvessel density for melanoma prognosis. Histopathology 2005; 47: 186-94.
15. Demirkesen C, Büyükpinarbasili N, Ramazanoǧlu R, et al,. The correlation of angiogenesis with metastasis in primary cutaneous melanoma: a comparative analysis of microvessel density, expression of vascular endothelial growth factor and basic fibroblastic growth factor. Pathology 2006; 38: 132-7.
16. Weidner N, Semple JP, Welch WR, Folkman J,. Tumor angiogenesis and metastasis. Correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
17. Vermeulen PB, Gasparini G, Fox SB, et al,. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002; 38: 1564-79.
18. Hasan J, Byers R, Jayson GC,. Intra-tumoural microvessel density in human solid tumours. Br J Cancer 2002; 86: 1566-77.
19. Vermeulen PB, Gasparini G, Fox SB, et al,. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1966; 32A: 2474-84.
20. Welter M, Bartha K, Rieger H,. Vascular remodelling of an arterio-venous network during solid tumour growth. J Theor Biol 2009; 259: 405-22.
21. Essner R, Scheri R, Kavanagh M, et al,. Surgical management of the groin lymph nodes in melanoma in the era of sentinel lymph node dissection. Arch Surg 2006; 141: 877-82.
22. Balch CM, Buzaid AC, Soong SJ, et al,. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-48.
23. Cuchet E, Pinel N, Corcella D, et al,. Sentinel lymph node biopsy in cutaneous melanoma: outcome after 5-years follow-up. Eur J Dermatol 2007; 17: 387-91.
24. Wang J, Guo Y, Wang B, et al,. Lymphatic microvessel density and vascular endothelial growth factor-C and -D as prognostic factors in breast cancer: a systematic review and meta-analysis of the literature. Mol Biol Rep 2012; 39: 11153-65.
25. Wang J, Li K, Wang B, Bi J,. Lymphatic microvessel density as a prognostic factor in non-small cell lung carcinoma: a meta-analysis of the literature. Mol Biol Rep 2012; 39: 5331-8.
26. Schoppmann SF, Jesch B, Zacherl J, et al,. Lymphangiogenesis and lymphovascular invasion diminishes prognosis in esophageal cancer. Surgery 2013; 153: 526-34.
27. Dadras SS, Paul T, Bertoncini J, et al,. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 2003; 162: 1951-60.
28. Van der Auwera I, Cao Y, Tille JC, et al,. First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer 2006; 95: 1611-25.
29. Shields JD, Borsetti M, Rigby H, et al,. Lymphatic density and metastatic spread in human malignant melanoma. Br J Cancer 2004; 90: 693-700.
30. Swoboda A, Schanab O, Tauber S, et al,. MET expression in melanoma correlates with a lymphangiogenic phenotype. Hum Mol Genet 2012; 21: 3387-96.
31. McShane LM, Altman DG, Sauerbrei W, et al,. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005; 97: 1180-4.
32. Altman DG,. Systematic reviews of evaluations of prognostic variables. BMJ 2001; 323: 224-8.
33. Altman DG, McShane LM, Sauerbrei W, Taube SE,. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med 2012; 10: 51.
34. Srivastava A, Laidler P, Davies RP, et al,. The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study. Am J Pathol 1988; 133: 419-23.
35. Carnochan P, Briggs JC, Westbury G, Davies AJ,. The vascularity of cutaneous melanoma: a quantitative histological study of lesions 0.85-1.25 mm in thickness. Br J Cancer 1991; 64: 102-7.
36. Barnhill RL, Busam KJ, Berwick M, et al,. Tumour vascularity is not a prognostic factor for cutaneous melanoma. Lancet 1994; 344: 1237-8.
37. Graham CH, Rivers J, Kerbel RS, et al,. Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas. Am J Pathol 1994; 145: 510-14.
38. Busam KJ, Berwick M, Blessing K, et al,. Tumor vascularity is not a prognostic factor for malignant melanoma of the skin. Am J Pathol 1995; 147: 1049-56.
39. Guffey JM, Chaney JV, Stevens GL, et al,. Immunohistochemical assessment of tumor vascularity in recurrent Clark II melanomas using antibody to type IV collagen. J Cutan Pathol 1995; 22: 122-7.
40. Marcoval J, Moreno A, Graells J, et al,. Vascular density and survival in cutaneous melanoma. Br J Dermatol 1996; 134: 809-10.
41. Ilmonen S, Kariniemi AL, Vlayakova T, et al,. Prognostic value of tumour vascularity in primary melanoma. Melanoma Res 1999; 9: 273-8.
42. Neitzel LT, Neitzel CD, Mangee KL, Malafa MP,. Angiogenesis correlates with metastasis in melanoma. Ann Surg Oncol 1999; 6: 70-4.
43. Dawn G, MacKie RM,. Expression of endoglin in human melanocytic lesions. Clin Exp Dermatol 2002; 27: 153-6.
44. Kashani-Sabet M, Sagebiel RW, Ferreira CM, et al,. Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J Clin Oncol 2002; 20: 1826-31.
45. Massi D, Franchi A, Borgognoni L, et al,. Tumor angiogenesis as a prognostic factor in thick cutaneous malignant melanoma. A quantitative morphologic analysis. Virchows Arch 2002; 440: 22-8.
46. Ribatti D, Ennas MG, Vacca A, et al,. Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest 2003; 33: 420-5.
47. Hillen F, van de Winkel A, Creytens D, et al,. Proliferating endothelial cells, but not microvessel density, are a prognostic parameter in human cutaneous melanoma. Melanoma Res 2006; 16: 453-7.
48. Kiss J, Timar J, Somlai B, et al,. Association of microvessel density with infiltrating cells in human cutaneous malignant melanoma. Pathol Oncol Res 2007; 13: 21-31.
49. Storr SJ, Safuan S, Mitra A, et al,. Objective assessment of blood and lymphatic vessel invasion and association with macrophage infiltration in cutaneous melanoma. Mod Pathol 2012; 25: 493-504.
50. de Waal RM, van Altena MC, Erhard H, et al,. Lack of lymphangiogenesis in human primary cutaneous melanoma. Consequences for the mechanism of lymphatic dissemination. Am J Pathol 1997; 150: 1951-7.
51. Straume O, Jackson DG, Akslen LA,. Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma. Clin Cancer Res 2003; 9: 250-6.
52. Sahni D, Robson A, Orchard G, et al,. The use of LYVE-1 antibody for detecting lymphatic involvement in patients with malignant melanoma of known sentinel node status. J Clin Pathol 2005; 58: 715-21.
53. Massi D, Puig S, Franchi A, et al,. Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study. J Clin Pathol 2006; 59: 166-73.
54. Xu X, Gimotty PA, Guerry D, et al,. Lymphatic invasion revealed by multispectral imaging is common in primary melanomas and associates with prognosis. Hum Pathol 2008; 39: 901-9.
55. Shayan R, Karnezis T, Murali R, et al,. Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis. Histopathology 2012; 61: 702-10.
56. Niakosari F, Kahn HJ, McCready D, et al,. Lymphatic invasion identified by monoclonal antibody D2-40, younger age and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma. Arch Dermatol 2008; 144: 462-7.
57. Petitt M, Allison A, Shimoni T, et al,. Lymphatic invasion detected by D2-40/S-100 dual immunohistochemistry does not predict sentinel lymph node status in melanoma. J Am Acad Dermatol 2009; 61: 819-28.
58. Doeden K, Ma Z, Narasimhan B, et al,. Lymphatic invasion in cutaneous melanoma is associated with sentinel lymph node metastasis. J Cutan Pathol 2009; 36: 772-80.
59. Petersson F, Diwan AH, Ivan D, et al,. Immunohistochemical detection of lymphovascular invasion with D2-40 in melanoma correlates with sentinel lymph node status, metastasis and survival. J Cutan Pathol 2009; 36: 1157-63.
60. Fohn LE, Rodriguez A, Kelley MC, et al,. D2-40 lymphatic marker for detecting lymphatic invasion in thin to intermediate thickness melanomas: association with sentinel lymph node status and prognostic value-a retrospective case study. J Am Acad Dermatol 2011; 64: 336-45.
61. Xu X, Chen L, Guerry D, et al,. Lymphatic invasion is independently prognostic of metastasis in primary cutaneous melanoma. Clin Cancer Res 2012; 18: 229-37.
62. Rinderknecht M, Detmar M,. Tumor lymphangiogenesis and melanoma metastasis. J Cell Physiol 2008; 216: 347-54.
63. Skobe M, Hamberg LM, Hawighorst T, et al,. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol 2001; 159: 893-903.
64. Schietroma C, Cianfarani F, Lacal PM, et al,. Vascular endothelial growth factor-C expression correlates with lymph node localization of human melanoma metastases. Cancer 2003; 98: 789-97.
65. Vihinen PP, Hilli J, Vuoristo MS, et al,. Serum VEGF-C is associated with metastatic site in patients with malignant melanoma. Acta Oncol 2007; 46: 678-84.
66. Cianfarani F, Mastroeni S, Odorisio T, et al,. Expression of vascular endothelial growth factor-C in primary cutaneous melanoma predicts sentinel lymph node positivity. J Cutan Pathol 2012; 39: 826-34.
67. Hirakawa S, Brown LF, Kodama S, et al,. VEGF-C induced lymphangiogenesis in sentinel lymph nodes promotes tumour metastasis to distant sites. Blood 2007; 109: 1010-17.
68. Tanaka F, Otake Y, Yanagihara K, et al,. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 2001; 7: 3410-15.
69. Potente M, Gerhardt H, Carmeliet P,. Basic and therapeutic aspects of angiogenesis. Cell 2011; 146: 873-87.